Background
albuminuria, CKD, chronic kidney disease, residual renal deterioration, diabetic, impairment of kidney function, albuminuric, T2DM, diabetes
HYPERTENSION, DIABETES
The prevalence of chronic kidney disease (CKD) has increased in recent decades alongside an increase in diabetes and hypertension, the main drivers of CKD [Renin-angiotensin system (RAS) blockers, such as angiotensin converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs), in the context of a multifactorial risk minimization strategy have been tested for their ability to revert CKD progression or at least prevent its further deterioration and were included in guidelines as a standard therapy for diabetic patients with CKD [One of the potential reasons for the residual renal deterioration is an increase in aldosterone levels which are elevated in up to 50% of patients treated with RAS blockers within a year of initiating treatment, leading to increases in albuminuria and impairment of kidney function [We were interested in the coverage of these two clinical trials for T2DM patients with CKD in Germany. As we recently published data on the prevalence of CKD [Differences between the CKD population documented in DPV/DIVE and the population that was part of the combined finerenone clinical trials (FIDELITY).The coverage of the FIDELITY CKD population focusing on albuminuric patients compared with CKD patients included in the registry (DPV and DIVE).The impact of the baseline requirement of the prescription of ACEi or ARBs for the study population to be in line with guideline-recommendations AND the coverage of the FIDELITY population for patients with CKD within DPV/DIVE when all the CKD criteria, the requirement for ACEi/ARB treatment at baseline, and all the further inclusion and exclusion criteria were applied.